HK1165954A1 - Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors - Google Patents

Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors

Info

Publication number
HK1165954A1
HK1165954A1 HK12106517.7A HK12106517A HK1165954A1 HK 1165954 A1 HK1165954 A1 HK 1165954A1 HK 12106517 A HK12106517 A HK 12106517A HK 1165954 A1 HK1165954 A1 HK 1165954A1
Authority
HK
Hong Kong
Prior art keywords
nitrogen
heterocyclic compounds
fused heterocyclic
beta amyloid
containing fused
Prior art date
Application number
HK12106517.7A
Other languages
English (en)
Inventor
Noritaka Kitazawa
Daisuke Shinmyo
Koichi Ito
Nobuaki Sato
Daiju Hasegawa
Toshiyuki Uemura
Toru Watanabe
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of HK1165954A1 publication Critical patent/HK1165954A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK12106517.7A 2009-02-26 2012-07-04 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors HK1165954A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15569709P 2009-02-26 2009-02-26
JP2009043337 2009-02-26
PCT/JP2010/053368 WO2010098487A1 (en) 2009-02-26 2010-02-24 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors

Publications (1)

Publication Number Publication Date
HK1165954A1 true HK1165954A1 (en) 2012-10-12

Family

ID=42331601

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12106517.7A HK1165954A1 (en) 2009-02-26 2012-07-04 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors

Country Status (17)

Country Link
US (1) US8754100B2 (ru)
EP (2) EP2401276B1 (ru)
JP (1) JP2012519152A (ru)
KR (1) KR20110122746A (ru)
CN (1) CN102333777B (ru)
AR (1) AR075606A1 (ru)
AU (1) AU2010218714A1 (ru)
CA (1) CA2753696A1 (ru)
HK (1) HK1165954A1 (ru)
IL (1) IL214780A (ru)
MX (1) MX2011008501A (ru)
NZ (1) NZ594776A (ru)
PE (1) PE20120172A1 (ru)
RU (1) RU2515976C2 (ru)
SG (1) SG173710A1 (ru)
TW (1) TW201035101A (ru)
WO (1) WO2010098487A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CA2713716A1 (en) 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
WO2010040661A1 (en) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
EP2355817A1 (en) 2008-11-10 2011-08-17 F. Hoffmann-La Roche AG Heterocyclic gamma secretase modulators
CA3017886A1 (en) 2008-11-19 2010-05-27 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
JP5576403B2 (ja) 2009-02-06 2014-08-20 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γ分泌酵素調節物質としての新規置換二環複素環化合物
CN102439005B (zh) 2009-05-07 2015-07-22 杨森制药公司 作为γ-分泌酶调节剂的取代的吲唑和氮杂-吲唑衍生物
MX2011011972A (es) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals Inc Tratamiento de trastornos cognitivos con determinados receptores de acido nicotinico alfa-7 en combinacion con inhibidores de acetilcolinesterasa.
US20120142672A1 (en) * 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
BR112012000915A2 (pt) 2009-07-15 2019-09-24 Janssen Pharmaceuticals Inc derivados de triazol e imidazol substituídos como moduladores de gama secretase.
US9145399B2 (en) 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
DK3029039T3 (en) 2010-05-17 2017-12-04 Forum Pharmaceuticals Inc PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE
JP6069661B2 (ja) 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
CA2809779A1 (en) 2010-09-02 2012-03-08 Takeda Pharmaceutical Company Limited Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
AU2012230348A1 (en) 2011-03-24 2013-08-29 Cellzome Limited Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
WO2013005354A1 (ja) * 2011-07-01 2013-01-10 武田薬品工業株式会社 複素環化合物
KR101913135B1 (ko) * 2011-07-15 2018-10-30 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체
WO2013106328A1 (en) * 2012-01-09 2013-07-18 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes for treatment of early onset alzheimer's disease
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
NZ702611A (en) 2012-05-16 2016-10-28 Cellzome Ltd Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
EP2953949B1 (en) 2012-12-20 2016-09-28 Janssen Pharmaceutica NV Novel tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
JP6283691B2 (ja) 2013-01-17 2018-02-21 ヤンセン ファーマシューティカ エヌ.ベー. γセクレターゼ調節剤としての新規な置換ピリド−ピペラジノン誘導体
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
CN103910781B (zh) * 2014-03-18 2016-02-17 重庆大学 一种Aβ聚集抑制剂
WO2016070107A1 (en) 2014-10-31 2016-05-06 The General Hospital Corporation Potent gamma-secretase modulators
EP3031458A1 (en) 2014-12-09 2016-06-15 Iproteos S.L. Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits
TWI696617B (zh) * 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
PL3846903T3 (pl) * 2018-09-03 2024-05-06 F. Hoffmann-La Roche Ag Bicykliczne pochodne heteroarylowe
CN110642689B (zh) * 2019-09-05 2022-06-24 南通大学 一种3,6-二溴-2-甲基苯甲醛及其化学合成方法
CN112661639A (zh) * 2020-12-07 2021-04-16 浙江工业大学 一种4-乙酰丁酸酯类化合物合成方法
CN116621846B (zh) * 2023-07-24 2023-10-17 华润医药研究院(深圳)有限公司 双环杂环及三环杂环类化合物及其制备方法和医药用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA54393C2 (ru) * 1995-04-21 2003-03-17 Н'Юросерч А/С Соединения бензимидазола, фармацевтические композиции, содержащие эти соединения и способ лечения чувствительных к положительной модуляции гамк-рецепторных комплексов расстройств цнс
IL131618A0 (en) * 1997-04-16 2001-01-28 Abbott Lab 5,7-Disubstituted aminopyrido [2,3-D] pyrimidine compounds and their use as adenosine kinase inhibitors
US7244739B2 (en) * 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
KR100966749B1 (ko) 2004-05-26 2010-06-30 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
MY144960A (en) 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
GEP20115139B (en) 2006-03-09 2011-01-10 Eisai R&D Man Co Ltd Polycyclic cinnamide derivative
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
TW200848054A (en) 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
EP2229381A1 (en) 2007-12-06 2010-09-22 Schering Corporation Gamma secretase modulators
WO2010025197A1 (en) 2008-08-27 2010-03-04 Eisai R&D Management Co., Ltd. Process for preparing certain cinnamide compounds
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
PL2401270T3 (pl) 2009-02-26 2014-03-31 Glaxo Group Ltd Pochodne pirazolu stosowane jako antagoniści receptora CCR4
BRPI1007883A2 (pt) 2009-02-26 2016-02-23 Eisai R&D Man Co Ltd sal, e, cristal.
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
MY153941A (en) 2009-02-26 2015-04-15 Boehringer Ingelheim Int Compounds as bradykinin b1 antagonists
BR112012000915A2 (pt) 2009-07-15 2019-09-24 Janssen Pharmaceuticals Inc derivados de triazol e imidazol substituídos como moduladores de gama secretase.
WO2011031984A2 (en) 2009-09-11 2011-03-17 Simplisse, Inc. Nipple shield

Also Published As

Publication number Publication date
CN102333777B (zh) 2014-06-25
CN102333777A (zh) 2012-01-25
RU2515976C2 (ru) 2014-05-20
EP2615090A1 (en) 2013-07-17
KR20110122746A (ko) 2011-11-10
US20120053171A1 (en) 2012-03-01
TW201035101A (en) 2010-10-01
US8754100B2 (en) 2014-06-17
EP2401276A1 (en) 2012-01-04
AR075606A1 (es) 2011-04-20
MX2011008501A (es) 2011-09-01
JP2012519152A (ja) 2012-08-23
EP2401276B1 (en) 2013-06-05
AU2010218714A1 (en) 2011-09-08
PE20120172A1 (es) 2012-03-08
CA2753696A1 (en) 2010-09-02
WO2010098487A1 (en) 2010-09-02
RU2011139132A (ru) 2013-04-20
IL214780A0 (en) 2011-11-30
IL214780A (en) 2014-06-30
SG173710A1 (en) 2011-09-29
NZ594776A (en) 2013-05-31

Similar Documents

Publication Publication Date Title
HK1165954A1 (en) Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
AR121612A2 (es) Inhibidores de glucosilceramida sintasa
TN2011000400A1 (en) Inhibitors of beta-secretase
MY177250A (en) Novel nicotinamide derivative or salt thereof
TN2012000125A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
MX2013005533A (es) Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep.
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
EA201071370A1 (ru) Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы
MY148703A (en) Polycyclic cinnamide derivatives
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
IN2014MN01521A (ru)
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
ECSP11011196A (es) Derivados de piperidina
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
MX2012007836A (es) Derivados de acido carboxilico heterociclicos que comprenden un anillo de oxazolopirimidina 2,5-sustituida.
MX2012007834A (es) Derivados de acido carboxilico que comprenden un anillo de oxazolopirimidina 2,5-sustituido.
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
PE20140239A1 (es) Derivados de 1,4-oxazepano
MX345264B (es) Derivado de azol.
EA201591487A1 (ru) Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170224